Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
Division of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, USA.
Sci Transl Med. 2018 Apr 11;10(436). doi: 10.1126/scitranslmed.aan3464.
Patients undergoing surgical resection of primary breast tumors confront a risk for metastatic recurrence that peaks sharply 12 to 18 months after surgery. The cause of early metastatic relapse in breast cancer has long been debated, with many ascribing these relapses to the natural progression of the disease. Others have proposed that some aspect of surgical tumor resection triggers the outgrowth of otherwise-dormant metastases, leading to the synchronous pattern of relapse. Clinical data cannot distinguish between these hypotheses, and previous experimental approaches have not provided clear answers. Such uncertainty hinders the development and application of therapeutic approaches that could potentially reduce early metastatic relapse. We describe an experimental model system that definitively links surgery and the subsequent wound-healing response to the outgrowth of tumor cells at distant anatomical sites. Specifically, we find that the systemic inflammatory response induced after surgery promotes the emergence of tumors whose growth was otherwise restricted by a tumor-specific T cell response. Furthermore, we demonstrate that perioperative anti-inflammatory treatment markedly reduces tumor outgrowth in this model, suggesting that similar approaches might substantially reduce early metastatic recurrence in breast cancer patients.
患者在接受原发性乳腺肿瘤切除术时,面临着术后 12 至 18 个月时转移复发风险急剧上升的问题。乳腺癌早期转移复发的原因长期以来一直存在争议,许多人将这些复发归因于疾病的自然进展。另一些人则提出,手术切除肿瘤的某些方面触发了原本休眠的转移的生长,导致复发呈同步模式。临床数据无法区分这些假设,以前的实验方法也没有提供明确的答案。这种不确定性阻碍了潜在的治疗方法的发展和应用,这些方法可能会降低早期转移复发的风险。我们描述了一个实验模型系统,该系统明确将手术和随后的伤口愈合反应与远处解剖部位的肿瘤细胞生长联系起来。具体来说,我们发现手术后诱导的全身炎症反应促进了肿瘤的出现,否则这些肿瘤的生长会受到肿瘤特异性 T 细胞反应的限制。此外,我们还证明,围手术期抗炎治疗可显著减少该模型中的肿瘤生长,这表明类似的方法可能会显著降低乳腺癌患者的早期转移复发率。